InVitro International
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- InVitro International, Inc. (OTCQB: IVRO) develops, manufactures, and markets in vitro assay kits and systems for non-animal testing to detect, rank, and predict the potential irritancy, toxicity, or corrosivity of substances to human eye and skin tissue; its core products include the Irritection Assay System (OECD 496), a standardized quantitative method utilizing macromolecular changes to assess ocular and dermal irritancy of chemicals, mixtures, and formulations for cosmetics, personal care, and chemical manufacturers; Corrositex (OECD 435), a biomembrane-based non-animal test approved by the US Department of Transportation for determining skin corrosivity, GHS/UN Packing Group classifications, and environmental safety compliance for hazardous materials transport; and customized laboratory services encompassing standard testing, independent irritancy/corrosivity evaluations, technology installation, consultation, and data analysis from decades of test results. The company, founded in 1985 and headquartered in Placentia, California, serves socially conscious manufacturers worldwide, including cosmetics, chemicals, and industrial sectors, with global distribution through laboratory service partners and operations spanning the United States, Europe, and other international markets. In recent developments, InVitro International signed a Memorandum of Understanding in January 2025 to merge with an unnamed European-based non-animal testing organization operating for over 20 years, aligning with its mergers-and-acquisitions growth strategy to expand in the European market where non-animal testing originated; the company engaged Askew Kabala and Company, Inc. in September 2024 for business advising, investment banking, management, and strategy services to advance its corporate growth plan amid post-Covid recovery; it reported strong fiscal 2025 results, including Q3 sales of $234,430 (up 39.7% year-over-year) and year-to-date net income of $95,556 (up 17.1%), supported by regulatory tailwinds such as Canada's cosmetics animal testing ban and US government acceptance of validated in vitro methods; and continues planning an uplisting to OTCQB for enhanced visibility.
Continuing the Cause; Humane Global Animal Welfare
InVitro International & the World's Animals Look Forward to 2026
Game Changing Signals from Global Regulatory Agencies Accompany IVRO Sales and Profit Gains
IVRO's Q3 Packed with Positives; Sales, Profits, and U.S. Government/Global Support for Animal Welfare
IVRO Announces Strong FY '25 First Quarter Sales & Net Income Advances
IVRO Signs MOU to Merge With a European Based Non-Animal Testing Focused Organization
InVitro International: Expectations Remain High for Animal Welfare & Growth Opportunities
InVitro International Engages Askew Kabala and Company, Inc. to Further Advance Its Corporate Growth Plan
InVitro International Progresses with Growth Strategies and Continues Profitability
InVitro International Reports Positive First Half and Second Quarter FY '24 Results; Also Planning an OTC Markets Uplisting
InVitro International Sees Real Positives in Start to FY '24
InVitro International Announces Fiscal Year End 2023 and Continues Positives
IVRO Announces Fiscal Q #3 2023 Results While Continuing M&A Strategy to Make Non-Animal Testing Famous